Biomarkers to predict prognosis and response to checkpoint inhibitors

Nivolumab is a fully human immunoglobulin (Ig) G4 antibody that selectively inhibits the programmed death 1 (PD-1) immune checkpoint molecule, and has recently been launched for the treatment of renal cell cancer (RCC) in Japan. Based on its promising anti-tumor efficacy and manageable safety profil...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuasa, Takeshi, Masuda, Hitoshi, Yamamoto, Shinya, Numao, Noboru, Yonese, Junji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Japan 2017
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5533827/
https://www.ncbi.nlm.nih.gov/pubmed/28382562
http://dx.doi.org/10.1007/s10147-017-1122-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5533827/
https://www.ncbi.nlm.nih.gov/pubmed/28382562
http://dx.doi.org/10.1007/s10147-017-1122-1

Ejemplares similares